The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effectiveness of adjuvant chemoradiotherapy for oral cavity squamous cell carcinoma with minor and major extranodal extension: A multi-institutional consortium study.
 
Mirko Manojlovic Kolarski
No Relationships to Disclose
 
Jie Su
No Relationships to Disclose
 
Ilan Weinreb
No Relationships to Disclose
 
Bayardo Perez-Ordonez
No Relationships to Disclose
 
Snehal G. Patel
Patents, Royalties, Other Intellectual Property - US patent #US9554857 B2 issued Jan 31, 2017 for “Apparatus, system and method for providing laser steering and focusing for incision, excision and ablation of tissue in minimally-invasive surgery.”
 
Cristina Valero
No Relationships to Disclose
 
Bin Xu
No Relationships to Disclose
 
Nora Katabi
No Relationships to Disclose
 
Jonathan Clark
No Relationships to Disclose
 
Tsu-Hui (Hubert) Low
No Relationships to Disclose
 
Ruta Gupta
No Relationships to Disclose
 
Evan Michael Graboyes
Honoraria - Castle Biosciences
Other Relationship - National Cancer Institute
 
Joel C Davies
No Relationships to Disclose
 
Mary Richardson
No Relationships to Disclose
 
David Paul Goldstein
Stock and Other Ownership Interests - Pfizer (I)
 
Shao Hui Huang
No Relationships to Disclose
 
Brian O'Sullivan
Consulting or Advisory Role - Merck
 
Wei Xu
No Relationships to Disclose
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)
 
John R de Almeida
No Relationships to Disclose